Astellas Pharma and AstraZeneca have announced the approval of the dry-power inhaler Symbicort Turbuhaler for the additional indication of chronic obstructive pulmonary disease(COPD). Symbicort Turbuhaler is a combination product ...
Tags: Astellas Pharma, AstraZeneca, dry-power inhaler Symbicort Turbuhaler